Q-omics provides the consensus-scored ZNF581 profile across patient tissues and cancer cell-line models. ZNF581 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF581 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ZNF581 RNA expression shows 18,539 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where ZNF581 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF581 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF581 survival associations across molecular data types. ZNF581 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF581 RNA expression–survival associations across cancer types. High ZNF581 expression shows unfavorable associations in ACC, LIHC, LGG and THCA, but favorable associations in UVM and GBM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF581 RNA expression.
This table summarizes ZNF581 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF581. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF581 shows higher tumor expression in KIRC, THCA, KIRP, COAD, LIHC and BLCA. The KIRC box plot shows higher ZNF581 RNA expression in tumor versus normal tissue (log2 FC = +1.082, t-test p < 0.001).
This table shows molecular features associated with ZNF581 in patient tissues and cancer cell lines. In patient samples, ZNF581 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF581 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUAD.
